ArticleJournal of gynecologic oncology2026
Prognostic significance of psoas muscle index at diagnosis in cervical cancer progression.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether the psoas muscle index (PMI) measured using computed tomography (CT) at diagnosis can predict cancer progression and overall survival (OS) in patients with cervical cancer.
methodsWe retrospectively reviewed the medical records of patients diagnosed with cervical cancer at Korea University Anam Hospital from January 2019 to December 2023. Patients with incomplete data or those who were lost to follow-up were excluded. PMI was measured on axial CT images at the third lumbar vertebral (L3) level at diagnosis, defined as the sum of bilateral psoas diameters normalized to height squared (m²), and a cutoff value of 35 mm/m² was used to classify patients into low and high PMI groups. Survival outcomes were assessed using Kaplan-Meier analysis and the log-rank test. Cox proportional hazards models were used to identify prognostic factors.
resultsOf the 178 patients, 92 were in the low PMI group and 86 in the high PMI group. Higher PMI was associated with significantly prolonged disease-free survival (DFS) (p<0.001), but not with OS (p=0.395). In multivariate Cox regression analysis, higher PMI independently predicted a lower likelihood of disease progression (adjusted hazard ratio, 0.30; p<0.001). However, PMI was not associated with OS.
conclusionThis study demonstrates that PMI measured at diagnosis may serve as a useful independent prognostic factor for cancer progression in patients with cervical cancer, particularly for predicting DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.